Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan

BACKGROUND: Eculizumab was approved for atypical haemolytic uraemic syndrome (aHUS) in Japan in 2013. Post-marketing surveillance (PMS) was mandated by regulatory authorities to assess the safety and effectiveness of eculizumab in patients with aHUS in a real-world setting. METHODS: Paediatric patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Shuichi, Hataya, Hiroshi, Ashida, Akira, Hamada, Riku, Ishikawa, Tomoaki, Ishikawa, Yumiko, Shimono, Akihiko, Konomoto, Takao, Miyazawa, Tomoki, Ogura, Masao, Tanaka, Kazuki, Kagami, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923705/
https://www.ncbi.nlm.nih.gov/pubmed/35438790
http://dx.doi.org/10.1093/ndt/gfac150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9923705/
https://www.ncbi.nlm.nih.gov/pubmed/35438790
http://dx.doi.org/10.1093/ndt/gfac150

Ejemplares similares